Kensey Nash Reviewing TriActiv Distal Protection Marketing Options
This article was originally published in The Gray Sheet
Executive Summary
Completion of the 50-center, 800-patient, randomized U.S. PRIDE trial of the TriActiv distal protection system in coming months will clear the way for a 510(k) submission by year-end, Kensey Nash says
You may also be interested in...
Kensey Nash TriActiv Safety With Small Guiding Catheters Is Equal To Control
Kensey Nash's TriActiv distal protection system for saphenous vein graft interventions is associated with significantly more in-hospital hemorrhagic/vascular events than controls in the firm's PRIDE trial
Kensey Nash TriActiv Safety With Small Guiding Catheters Is Equal To Control
Kensey Nash's TriActiv distal protection system for saphenous vein graft interventions is associated with significantly more in-hospital hemorrhagic/vascular events than controls in the firm's PRIDE trial
Embolic Protection Competition Fueled By Next-Generation Devices
Rapid-exchange versions of Possis Medical's AngioJet XMI and XVG catheters will make the thrombectomy device line a more attractive option for cath labs in the U.S. and abroad, the firm predicts